Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML

Blood

Volumn 123, Issue 15, 2014, Pages 2412-2415

  Havelange, Violaine ^a,b,c   Ranganathan, Parvathi ^a,b   Geyer, Susan ^a,b,d   Nicolet, Deedra ^a,b,d   Huang, Xiaomeng ^a,b   Yu, Xueyan ^a,b   Volinia, Stefano ^a,b   Kornblau, Steven M ^d   Andreeff, Michael ^d   Croce, Carlo M ^a,b   Marcucci, Guido ^a,b   Bloomfield, Clara D ^a,b   Garzon, Ramiro ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; MICRORNA; MICRORNA 10; NUCLEOPHOSMIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN RECEPTOR; LILRB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL LINE; CELL PROLIFERATION; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; DNA MICROARRAY; DRUG RESISTANCE; GENETICS; MUTATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MEMBRANE GLYCOPROTEINS; MUTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, IMMUNOLOGIC;

EID: 84901717408     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-532374     Document Type: Article

References (15)

1. Falini B, Mecucci C, Tiacci E, et al GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266. (Pubitemid 40110814)
2. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol. 2009;21(6):573-581.
3. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431-448. (Pubitemid 46105936)
4. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775-789.
5. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117(4):1121-1129.
6. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183-3189.
7. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111(10):5078-5085.
8. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA. 2008;105(10):3945-3950. (Pubitemid 351723504)
9. Garzon R, Heaphy CE, Havelange V, et al. MiR-29b functions in AML. Blood. 2009;114(26):5331-5341.
10. Huang X, Schwind S, Yu B, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013;19(9):2355-2367.
11. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19(10):1760-1767. (Pubitemid 41486153)
12. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604.
13. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801-3808.
14. Zhang H, Luo XQ, Feng DD, et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer. 2011;10:108.
15. Schotte D, De Menezes RX, Akbari Moqadam F, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 2011;96(5):703-711.